首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Resminostat, a phase II clinical HDAC inhibitor, sensitizes tumor cells for NK cell response and synergizes with ADCC therapy
【24h】

Resminostat, a phase II clinical HDAC inhibitor, sensitizes tumor cells for NK cell response and synergizes with ADCC therapy

机译:Resminostat,II期临床HDAC抑制剂,敏感NK细胞响应的肿瘤细胞,并用ADCC疗法协同

获取原文
获取原文并翻译 | 示例
       

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号